Cellid, Co., Ltd. (KOSDAQ: 299660)

Market Cap	118.18B
Revenue (ttm)	914.19M
Net Income (ttm)	-10.36B
Shares Out	21.10M
EPS (ttm)	-815.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,639,371
Open	6,050.00
Previous Close	6,100.00
Day's Range	5,700.00 - 6,400.00
52-Week Range	1,733.00 - 17,310.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Cellid,

Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 299660